Literature DB >> 11571784

Sublytic C5b-9-stimulated Schwann cell survival through PI 3-kinase-mediated phosphorylation of BAD.

S Hila1, L Soane, C L Koski.   

Abstract

Sublytic C5b-9 induces cell cycle activation, proliferation, and rescue from apoptosis in Schwann cells. The signaling pathways for C5b-9-mediated rescue were investigated. Following serum withdrawal, DNA fragmentation, detected by TUNEL and FACS analysis, was 56.7% +/- 7.3 and 91.9% +/- 2.4 in cultured sciatic nerve Schwann cells from 6-day-old rats after 18 h and 24 h, respectively. Apoptosis was confirmed by inhibition of DNA fragmentation in a dose-dependent manner by DMQD-CHO, a caspase-3 inhibitor. Treatment with sublytic C5b-9 generated with purified components (C5*9) or Ab+C7-depleted serum (C7dHS)+C7 rescued 89% and 86% of Schwann cells, respectively, as compared with cells treated with C5*6, C8, C9, or Ab+C7dHS. Sublytic C5b-9 increased Schwann cell PI-3 kinase and Akt activity maximally at 5 min 3.14 +/- 0.5-fold and 3.56 +/- 0.4-fold, respectively, over controls. ERK-1 activity was maximally stimulated 2.98-fold at 15 min. Inhibition of PI-3 kinase by LY294002 abrogated the C5b-9-mediated Schwann cell rescue from apoptosis, while inhibition of ERK-1 with PD098,059 did not. PI-3 kinase-Akt pathway activation by C5b-9 induced, within 15 min, a 6.34 +/- 1.2-fold increase in BAD phosphorylation at Ser 136, but not at Ser 112. Downstream Bcl-x(L) protein was increased 2.61-fold +/- 0.34-fold by 18 h and 3.9-fold +/- 0.84-fold by 24 h over controls. LY294002 prevented both BAD phosphorylation at Ser 136 and Bcl-x(L) protein induction, while PD098,059 did not. Our data indicated that sublytic C5b-9 rescued Schwann cell from apoptosis via activation of PI-3 kinase-Akt, BAD phosphorylation on Ser 136 and increased expression of Bcl-x(L). Sublytic C5b-9 detected on Schwann cell in vivo during inflammatory neuropathy may facilitate survival of Schwann cell capable of remyelination. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11571784     DOI: 10.1002/glia.1095

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  12 in total

1.  Sublytic complement protects prostate cancer cells from tumour necrosis factor-α-induced cell death.

Authors:  L Liu; W Li; Z Li; M Kirschfink
Journal:  Clin Exp Immunol       Date:  2012-08       Impact factor: 4.330

Review 2.  Molecules involved in the crosstalk between immune- and peripheral nerve Schwann cells.

Authors:  Nevena Tzekova; André Heinen; Patrick Küry
Journal:  J Clin Immunol       Date:  2014-04-17       Impact factor: 8.317

Review 3.  Complement regulation and kidney diseases: recent knowledge of the double-edged roles of complement activation in nephrology.

Authors:  Masashi Mizuno; Yasuhiro Suzuki; Yasuhiko Ito
Journal:  Clin Exp Nephrol       Date:  2017-03-24       Impact factor: 2.801

4.  Cd59 and inflammation regulate Schwann cell development.

Authors:  Ashtyn T Wiltbank; Emma R Steinson; Stacey J Criswell; Melanie Piller; Sarah Kucenas
Journal:  Elife       Date:  2022-06-24       Impact factor: 8.713

5.  Fingolimod and related compounds in a spontaneous autoimmune polyneuropathy.

Authors:  Hye-Jung Kim; Cha-Gyun Jung; Danuta Dukala; Hyun Bae; Rafael Kakazu; Robert Wollmann; Betty Soliven
Journal:  J Neuroimmunol       Date:  2009-08-03       Impact factor: 3.478

6.  Complement Membrane Attack and Tumorigenesis: A SYSTEMS BIOLOGY APPROACH.

Authors:  Laurence D Towner; Richard A Wheat; Timothy R Hughes; B Paul Morgan
Journal:  J Biol Chem       Date:  2016-05-19       Impact factor: 5.157

7.  Response gene to complement 32 is required for C5b-9 induced cell cycle activation in endothelial cells.

Authors:  Matthew Fosbrink; Cornelia Cudrici; Cosmin A Tegla; Kateryna Soloviova; Takahiro Ito; Sonia Vlaicu; Violeta Rus; Florin Niculescu; Horea Rus
Journal:  Exp Mol Pathol       Date:  2009-01-07       Impact factor: 3.362

8.  Complement activation in the Parkinson's disease substantia nigra: an immunocytochemical study.

Authors:  David A Loeffler; Dianne M Camp; Stephanie B Conant
Journal:  J Neuroinflammation       Date:  2006-10-19       Impact factor: 8.322

Review 9.  Complement system in pathogenesis of AMD: dual player in degeneration and protection of retinal tissue.

Authors:  Milosz P Kawa; Anna Machalinska; Dorota Roginska; Boguslaw Machalinski
Journal:  J Immunol Res       Date:  2014-09-04       Impact factor: 4.818

10.  Implication of complement system and its regulators in Alzheimer's disease.

Authors:  Martin V Kolev; Marieta M Ruseva; Claire L Harris; B Paul Morgan; Rossen M Donev
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.